| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | BUY | BUY | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 7.10▼ | 7.11▼ | 7.11▼ | 7.01▲ | 6.99▲ |
| MA10 | 7.11▼ | 7.11▼ | 7.15▼ | 6.70▲ | 7.70▼ |
| MA20 | 7.11▼ | 7.15▼ | 7.04▲ | 6.92▲ | 7.24▼ |
| MA50 | 7.12▼ | 6.99▲ | 6.79▲ | 7.92▼ | 5.47▲ |
| MA100 | 7.15▼ | 6.75▲ | 6.81▲ | 7.02▲ | 5.04▲ |
| MA200 | 7.05▲ | 6.83▲ | 7.04▲ | 5.49▲ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.003▼ | -0.023▼ | -0.017▼ | 0.111▲ | -0.265▼ |
| RSI | 42.215▼ | 49.295▼ | 54.516▲ | 48.738▼ | 52.871▲ |
| STOCH | 31.944 | 20.454 | 37.750 | 66.185 | 13.383▼ |
| WILL %R | -100.000▼ | -87.302▼ | -60.000 | -23.596▲ | -80.970▼ |
| CCI | -163.682▼ | -81.038 | -54.428 | 78.311 | -85.987 |
|
Wednesday, September 24, 2025 04:21 AM
Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced its ...
|
|
Thursday, September 18, 2025 07:41 AM
Shares of companies focused on developing drugs for a liver condition called metabolic dysfunction-associated steatohepatitis (MASH) traded higher on Thursday after Roche (OTCQX:RHHBY) (OTCQX:RHHBF) ...
|
|
Wednesday, September 17, 2025 04:10 AM
Denifanstat met all primary and secondary endpoints versus placebo Denifanstat was generally well tolerated Sagimet initiated first-in-human Phase 1 clinical trial of a second FASN inhibitor, TVB-3567 ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 26/09/25 | 7.14 | 7.14 | 7.07 | 7.07 | 35,679 |
| 25/09/25 | 7.27 | 7.355 | 6.963 | 7.14 | 503,900 |
| 24/09/25 | 6.76 | 7.385 | 6.71 | 7.28 | 727,100 |
| 23/09/25 | 6.78 | 6.975 | 6.57 | 6.73 | 651,700 |
| 22/09/25 | 6.50 | 6.975 | 6.36 | 6.81 | 629,000 |
| 19/09/25 | 6.69 | 6.84 | 6.505 | 6.52 | 622,000 |
| 18/09/25 | 6.35 | 6.87 | 6.35 | 6.75 | 889,200 |
| 17/09/25 | 6.25 | 6.37 | 6.05 | 6.15 | 568,200 |
| 16/09/25 | 6.32 | 6.4191 | 6.12 | 6.20 | 595,669 |
| 15/09/25 | 6.91 | 6.93 | 6.29 | 6.36 | 566,869 |
|
|
||||
|
|
||||
|
|